**CURRICULUM VITAE**

David R. Gius, M.D., Ph.D.

Date of Birth: August 23, 1960

Place of Birth: Chicago, Illinois

Title: Associate Program Director

> NIH/Cambridge Scholars Graduate Program
>
> Chief, Molecular Radiation Oncology Section

Business Address: Radiation Oncology Branch,

> Center for Cancer Research, National Cancer Institute
>
> National Institutes of Health
>
> Bldg 10 3B43, Bethesda, MD 20892

# Tel. (301) 496-5457

> E-mail: <giusd@mail.NIH.gov>

[Education:]{.underline}

1980-1983 University of Illinois, at Chicago, Chicago, Illinois. (B.S.
Chemistry). Graduation June 12, 1983.

1983-1985 Loyola University of Chicago, Stritch School of Medicine,
Maywood, Illinois. Medical School years 1 and 2.

1985-1989 The University of Chicago, Department of Molecular Genetics
and Cell Biology, and the Committee on Virology, Chicago, Illinois.
Ph.D. conferred November 15, 1989. Laimonis A. Laimins, Supervisor.

1992. Loyola University of Chicago, Stritch School of Medicine, Maywood,
      Illinois. M.D. Medical School years 3 and 4. Graduation date June
      13, 1992.

[Employment:]{.underline}

1989-1990 Post Doctoral-Fellowship. The University of Chicago,
Department of Molecular Genetics and Cell Biology, Howard Hughes Medical
Institute, Chicago, IL. Supervisors Vikas P. Sukhatme, M.D., Ph.D. and
Tom Curran, Ph.D.

1991-1992 Post-Doctoral Fellowship. The University of Chicago,
Department of Radiation and Cellular Oncology, Chicago, IL. Ralph
Weichselbaum, M.D., Supervisor.

1992-1993 Transitional Resident, Weiss Memorial Hospital/The University
of Chicago, Chicago, IL.

1993-1994 Radiation Oncology Resident, Department of Radiation Oncology,
Radiation Oncology resident, University of Michigan Medical Center, Ann
Arbor, MI.

1994-1996 Radiation Oncology Resident, Radiation Oncology Center,
Malellinckrodt Institute of Radiology, Washington University School of
Medicine, St. Louis, MO.

1996-1997 ASTRO Fellow, Radiation Oncology Center, and Section of Cancer
Biology, Radiation Biology Mallinckrodt Institute of Radiology,
Washington University School of Medicine, St. Louis, MO.

1997-1999 Instructor, Radiation Oncology Center, and Section of Cancer
Biology, Mallinckrodt Institute of Radiology, Washington University
School of Medicine, St. Louis, MO.

1999-2001 Assistant Professor and Residency Director, Radiation Oncology
Center, and Section of Cancer Biology, Mallinckrodt Institute of
Radiology, Washington University School of Medicine, St. Louis, MO.

2001. Chief, Molecular Radiation Oncology Section, Residency Director,
      NCC Radiation Oncology Residency, and Clinical Director, GYN
      Services, Center for Cancer Research, National Cancer Institute,
      National Institute of Health, Bethesda, MD.

```{=html}
<!-- -->
```
2006. Associate Director, the National Institutes of Health
      Oxford/Cambridge Scholars Graduate Student Program, National
      Institute of Health, Bethesda, MD.

[Research Interests:]{.underline}

The central theme of the laboratory is the potential relationship of
intracellular pro-proliferative / pro-survival factors and how tumor
cells respond to therapeutic modalities. The laboratory's model systems,
both *in vitro* and *in vivo*, use tumor cells of squamous cell
carcinoma (SCCa) origin from malignancies of the cervix and head and
neck. This seems logical since these malignancies share similar tumor
biology, genetics, and epigenetics and a significant percentage of both
tumor types are infected with Human Papillomavirus that appears to play
a role in tumor progression. These model system are subsequently used in
both translation and basic science research projects to investigate the
mechanism of tumor cell resistance

The overarching goal of my research is an extension of the hypothesis
that tumor cells use pre-existing pro-survival signaling pathways,
up-regulated as a result of transformation or tumor micro-environment,
to evade the damaging and cytotoxic effects of anti-cancer agents. These
signaling factors are involved in the transmission of inter- and
intracellular information through multiple transduction cascades and it
has been suggested that one function is the activation of preprogrammed
reparative or protective cellular processes responding to intracellular
stress. Tumor cells likely activate these pathways responding to
dys-regulated cell division and the increased demands on multiple
cellular processes including increased replication, transcription,
translation, protein trafficking and the production of metabolites
(oxidative stress) that must be scavenged to prevent cellular stress.
Thus, we hypothesize that specific pro-survival pathways, both alone and
more likely in combination, and their upstream signaling factors are
potential molecular targets to improve the cytotoxic effects of
anti-cancer agents including but not limited to ionizing radiation.
These challenges have led our laboratory to concentrate its efforts into
two major areas of interests. The first involves constructing murine
models to investigate the role of aging in carcinogenesis that focuses
on the Sirtuin gene family that has been shown to regulate longevity as
well as defend against oxidative stress. These factors may confer
resistance to oxidative stress and loss of sirtuin function with age may
establish a phenotype permissive for cellular damage that results in
several age related illness including carcinogenesis, insulin
resistance, and cardiovascular disease. The second involves the idea
that oxidative stress induces methyltransferase activity and increases
gene expression of the pro-survival gene family. This involves of
insulator proteins and the role of *CTCF* and *CTCFL*/*BORIS* in the
regulation of gene expression and we hypothesis that BORIS may be
potential biomarkers and molecular targets to develop new anticancer
agents

[NIH Administrative and Educational Responsibilities:]{.underline}

I serve as the Associate Program Director for the NIH Oxford/Cambridge
Scholars Graduate Program that includes the Trans-NIH MD/PhD Partnership
Program at the National Institutes of Health. The NIH-United Kingdom
Scholars programs are a set of affiliated graduate programs designed to
offer accelerated international collaborative scientific research
training to highly accomplished students who are devoted to a career in
basic or clinical biomedical research. Students who successfully
matriculate through the program earn the Doctor of Philosophy (Ph.D. or
D.Phil.) degree. These programs include the National Institutes of
Health-Oxford University Scholars in Biomedical Research, the National
Institutes of Health-Cambridge University Health Science Scholars, the
National Institutes of Health-Marshall Scholars, the National Institutes
of Health-Rhodes Scholars, and the National Institutes of Health --
Wellcome Trust program.

I work directly with the Program Director, Dr. Michael Lenardo, in the
administration and management of all aspects of the Program. OxCam is
the largest graduate program at the NIH under the umbrella of the
Graduate Partnership Program (GPP). In this regard, I serve on the
Executive Committee, the Admissions Committee, and the Faculty
Collaborative Committee as well as developed the bylaws for this
program. I am also involved in representing the program in recruitment
of potential graduate applicants during the academic year as well as
involved in establishing an OxCam philanthropy program.

I also serve on the governing committee for the Radiation Research
Society that oversees the day to day functions of the Society including
planning the annual Radiation Research Scientific meeting. I sit on the
American Society of Radiation Oncology (ASTRO) Radiation and Cancer
Biology and Education and Grants Committees and the Education and Grants
committee is changed with funding young investigators and residents.

[Clinical, Service, and Education:]{.underline}

The Molecular Radiation Oncology section is part of the Radiation
Oncology Branch in the Center of Clinical Research. My position also
consisting of patient care (one day a week) as well as the development,
design, and the subsequent approval of clinical studies in the Section.
My primary clinical responsibilities include participation in the Head
and Neck and Gyn services and these responsibilities also integrate well
with my basic and translation science interests that center on model
systems using *in vitro* and *in vivo* squamous cell tumors and tumor
cell lines.

My responsibilities at the NCI also include participation in intramural
and extramural national committees as well as editorial review boards,
planning NCI related workshops, and various governmental and private
research study sections including Chairing the DOD PIM/RON-2 study
section. I am also involved with and have a strong commitment to the NCI
s long tradition of training and mentoring of students, post-doctoral
fellows, residents and physician-scientist. I recently complete my
second term as residency director. My trainees have enjoyed significant
success in both obtaining acceptance into graduate and medical programs,
matching in academic / research residency programs, and as junior
faculty. I consider education and service as a key aspect of both my
laboratory and my career goals and this is central to the mission at the
NCI.

I also serve on the governing committee for the Radiation Research
Society that oversees the day to day functions of the Society including
planning the annual Radiation Research Scientific meeting. I sit on the
American Society of Radiation Oncology (ASTRO) Radiation and Cancer
Biology and Education and Grants Committees and the Education and Grants
committee is changed with funding young investigators and residents.

[National Committees and Review Boards]{.underline}

External Adviser Committee, University of Virginia Cancer Center, (2008-
).

Councilor-Medicine, Radiation Research Society Governing Board,
(2007-2010).

Member, ASTRO Radiation & Cancer Biology Committee (2004 -2008).

Member, ASTRO Education and Research Committee (2007-2010).

Chair, Planning Committee, NCI Bi-Annual Radiation Oncology Young
Investigator Workshop, (2003, 2005, 2008), Bethesda, MD.

Intramural Committee Member, Grand Rounds Selection Committee, National
Cancer Institute, Bethesda, MD.

Intramural Committee Member, Gynecologic Cancers Progress Review Group
(GYN PRG) National Cancer Institute, Bethesda, MD.

Permanent Member IRB committee (2001 - 2004), National Cancer Institute,
National Institutes of Health, Bethesda, MD.

Member, CTEP committee (2001-2003), National Cancer Institute, National
Institutes of Health. Bethesda, MD.

[Editorial Boards]{.underline}

Cancer Research, Associate Editor, 2006.

Guest Editor for February 2006 Edition, Antioxidants & Redox Signaling,
2006.

International Journal of Radiation Oncology, Biology, and Physics,
Associate Editor, 2002.

Toxicology Letters, Associate Editor, 2002.

Cancer Investigation, Associate Editor, 1999.

[Study Section Reviewer]{.underline}

Department of Defense, Chair, PIM Study section, Breast Cancer Program -
2009.

Department of Defense, Chair, PIM/RON Study section, Prostate Cancer
Program - 2008.

National Cancer Institute, Radiation Study section -- 7/2006, 2/2007,
7/2007, 2/2008, 7/2008

Department of Defense, Breast Cancer Research Program - 2003, 2006.

Department of Defense, Prostate Cancer Research Program - 2000, 2001,
2002, 2004, 2005.

NASA, Low Dose Radiation Exposure and Carcinogenesis Program Study
Section - 6, 2008.

Israel Cancer Research Fund - 2003, 3004, 2005.

National Cancer Institute, Special Emphasis Panel - ZRG1 SSS-1, March
2003.

Canadian Institutes of Health Research, Cancer Section B, May 2002.

[Research Grants:]{.underline}

-   Bench to Bedside Research Award (10/2004 to 10/2006). "Novel
    approach for treatment of squamous cell malignancies with 17-AG and
    bortezomib". (\$100,000 per year for two years direct total costs).

-   American Cancer Society, Research Project Grant (07/2000 to
    06/2003). The role of heat shock and p38 in the cellular and
    cytotoxic response to IR. RPG TBE-100674 (\$385,605 direct and
    \$448,257 total cost).

-   The National Institute of Health, Program Project, Co-Project Leader
    (9/97 until 8/02). The regulation of the nuclear transcriptional
    factor, AP-1 in how H~2~O~2~ cultured cells gain resistance to
    multiple therapeutic modalities. PO1 CA75556 (\$103,000 direct -
    \$170,000 total cost/year).

-   The National Institute of Health, Mentor Clinical Scientist
    Development Award (K08). (9/97 until 8/01). p53 Independent
    Apoptosis in human T-Cells K08 CA72602-01. (\$403,390 direct and
    \$416,861 total cost).

-   The Radiological Society of North American (RSNA) Medical Student
    Department Award Program permits one medical student per year to
    work with a basic researcher in the Department of Radiology. Program
    supervisor: Dr. David Gius. (\$25,000 direct costs)

-   American Cancer Society, Institutional Research Grant (10/1999 to
    09/2000). The role of heat shock and cytoplasmic signaling factors
    in the cellular and cytotoxic response to ionizing radiation.
    (\$20,000 direct costs).

-   ROC Seed Grant. (02/98 to 02/99). Radiation Oncology Center, and
    Section of Cancer Biology, Mallinckrodt Institute of Radiology.
    Washington University School of Medicine, St. Louis, MO. The role of
    Redox Factor-1 in the cellular response to IR. (\$10,000 direct
    costs).

-   ASTRO Research Fellowship (07/96 until 06/97). Section of Cancer
    Biology, Washington University School of Medicine, St. Louis, MO.
    The role of cell cycle checkpoints in the cellular and cytotoxic
    response to ionizing radiation. (\$35,000 direct costs).

-   Fellowship grants for Residents from ASTRO, RSNA, ASCO, and the NIH
    are listed below.

[Clinical Protocols]{.underline}

Co-PI - A Pilot Study of Paclitaxel and Radiation Therapy For Locally
Advanced Squamous Cell Carcinoma of the Head and Neck.

Co-PI - Phase I Dose Escalation Study of the EGRF Tyrosine Kinase
Inhibitor ZD-1839 (Iressa) Combined with Paclitaxel (TAXOL®) and
External Beam Radiation Therapy in Patients with Advanced Squamous Cell
Carcinoma of the Head and Neck.

Co-PI - A Phase I Study of Concomitant Therapy with Proteasome Inhibitor
PS-341 and Radiation in Patients with Recurrent or Metastatic Squamous
Cell Carcinoma of the Head and Neck malignancies.

[Awards:]{.underline}

-   Graduate Training Fellowship (1987-1989). The Department of
    Molecular Genetics and Cell Biology, and the Committee on Virology.
    The University of Chicago, Chicago, IL.

-   Radiation Oncology Teacher of the Year, 1998. Radiation Oncology
    Center, Mallinckrodt Institute of Radiology, Washington University
    School of Medicine, St. Louis, MO.

[Educational Activity:]{.underline}

-   Jaime Leclerc. (2008 -- present). Vermont University. Research
    Fellow.

-   Krish Patel. (2007 - 2008). Duke Medical School, Clinical Intramural
    Research Training Award (CIRTA) Program Fellow from the University
    of Cincinnati School of Medicine, Cincinnati, OH.

-   Kristi Jacobs, Ph.D. Post-Doctoral Fellow (2006 to present).
    Molecular Biology, University of Maryland, Baltimore, MD.

-   Mark Mishra. (2006 - 2007). Resident, Radiation Oncology, Thomas
    Jefferson Medical School. Clinical Intramural Research Training
    Award (CIRTA) Program Fellow from the University of Cincinnati
    School of Medicine, Cincinnati, OH. An author on three manuscripts
    including a first author manuscript in *Mol. Can. Res*.

-   Dan Pennington (2005 - present). Currently a Ph.D. student in the
    NIH-Cambridge Graduate Program. Howard Hughes Medical Student
    Research Fellow (2005-2007) from the Eastern Virginia Medical
    School, Norfolk, VA. An author on three manuscripts from the
    laboratory.

-   JiJun Chen, M.D. Post-Doctoral Fellow (2006 to present). Previously
    a Fellow at Johns Hopkins Medical School, Baltimore, MD. An author
    on two manuscripts from the laboratory.

-   Tony Wang. (2005 - 2006). Resident, Radiation Oncology, Columbia
    Medical School. CIRTA Program Fellow from the University of Missouri
    Kansas City (UMKC) - School of Medicine, Kansas City, MO. He has a
    first author manuscript that is in preparation and is an author on
    three additional manuscripts from the laboratory.

-   Lei Huang, Ph.D. Senior Scientist FDA. Post-Doctoral Fellow (2004 to
    2007). Human Genetics, University of Baltimore, MD. An author on two
    manuscripts from the laboratory.

-   Lunching Sun, Ph.D. Post-Doctoral Fellow (2000 to present).
    Microbiology, University of Maryland, College Park, MD. An author on
    four manuscripts from the laboratory.

-   Rania Awwad. Research Fellow. B.S. in Biology. University of
    Virginia, Charlottesville, VA. Medical Student University of
    Virginia, 2005. An author on three manuscripts from the laboratory.

-   Allen Ho. (2003 - 2004). Resident at Stanford University Medical
    School, Stanford, CA. Howard Hughes Medical Student Research Fellow
    from the University of California Los Angles. Is an author on two
    manuscripts in including one published in Cancer Cell in November of
    2004.

-   Dee Dee Smart, M.D., Ph.D. (2003-2004). Radiation Oncology Resident,
    National Cancer Institute, National Institutes of Health,
    Bethesda, MD. Research Fellow. Is the first author on a manuscript
    published in Cancer Research and is an author on four additional
    manuscripts.

-   David Mattson, M.D. (2002-2004). Chief Resident, Radiation Oncology
    Program, University of Iowa Medical Center, Iowa City, IA. Research
    Fellow. An author on five manuscripts from the laboratory and is
    currently a Holman Research Training Residency Program.

-   Stephanie Markovina. (1998- 2002). Currently an MSTP student at the
    University of Wisconsin, Madison, WI. Symposia Speaker and Young
    Investigator and Travel Awardee, Radiation Research meeting (04/02).
    Undergraduate student. Co-first author, Cancer Research
    61:3486-3492**,** 2001 as well as an author on two addition
    publications.

-   Leah Shin (2001-2002). Radiology Resident, University of Indiana,
    Indianapolis, IN. Howard Hughes Medical Student Research Fellow.
    Speaker and Young Investigator and Travel Awardee, Radiation
    Research meeting (04/01). Author on two manuscripts.

-   Aradhana Kaushal, M.D. (2001-2002). Faculty Member, Radiation
    Oncology Branch, National Cancer Institute, National Institutes of
    Health, Bethesda, MD. Medical Student/Research Fellow. Was a
    Radiation Oncology Resident, Thomas Jefferson Hospitals.
    Philadelphia, PA. Co-first author on a submitted manuscript.
    Symposia Speaker and Young Investigator Awardee, Radiation Research,
    (04/02). She is an author on a manuscript in *Cancer Research*.

-   Lucio Laguna. (1999- 2001). Undergraduate student. Currently a
    graduate student, Department of Microbiology, Northwestern Medical
    School, Chicago, IL. First author on a manuscript in *Biochem
    Biophys Res Commun*. Speaker and Young Investigator Awardee,
    Radiation Research meeting (04/01).

-   Lilie Lin, M.D. (1999-2000). Resident Fellow. Assistant Professor,
    Hospital of Pennsylvania, Philadelphia, PA. Symposia Speaker and
    Young Investigator Awardee, Radiation Research, (05/032). Author,
    Oncogenes 12:6317-6327.

-   Shervin Karimpour, M.D. (1999-2001). Resident Fellow. Currently
    Clinical Chief, Radiation Oncology Branch, Center for Cancer
    Research, National Cancer Institute, National Institute of Health,
    Bethesda, MD. American Society of Clinical Oncology (ASCO) Young
    Investigator Award. (\$35,000 total direct costs). The Radiological
    Society of North American (RSNA) Fellowship Research Award
    ((\$40,000 total direct costs). Young Investigator Awardee and
    Symposia Speaker, Oxygen Society meeting (11/00). Young Investigator
    and Travel Awardee, Radiation Research meeting (04/01). First
    Author, Oncogene 12:6317-6327.

-   Junyang Lou, M.D., Ph.D. (2000-2001). Internal Medicine Resident,
    Duke University Medical School, Durham, N.C. Graduated MSTP 2006,
    Washington University School of Medicine. Author, Cancer Research
    60, 6688-6695.

-   Jay E. Locke, M.D. (1999- 2001). Assistant Professor, Radiation
    Oncology Center, Mallinckrodt Institute of Radiology, Washington
    University School of Medicine, St. Louis, MO. Resident/Research
    Fellow. The Radiological Society of North American (RSNA) Resident
    Research Award and RSNA Research Fellowship (\$40,000 total costs).
    The National Institute of Health, Mentor Clinical Scientist
    Development Award (K08). RE: 1KO8 (\$586,245 direct cost). First
    Author, Int. J. Radiat. Biol. 78:493-502.

-   Imran Zoberi, M.D. (1999-2000). Associate Professor and Residency
    Director, Radiation Oncology Center, and Section of Cancer Biology,
    Mallinckrodt Institute of Radiology, Washington University School of
    Medicine, St. Louis, MO. Resident/Research Fellow. American Society
    of Therapeutic Radiation Oncology (ASTRO) Research Fellowship Award.
    (\$35,000 total direct costs). First Author, Cancer Letters 175:
    165-173.

-   Jack S. Wei, M.D. (1997-1999). Assistant professor, University of
    Arizona, Tucson, AZ. Medical Student. First author, Cancer Research
    60, 6688-6695, and author on 3 additional manuscripts.

-   Heather A. Curry, M.D. (1998- 2000). Assistant Professor, Department
    of Radiation Oncology, Thomas Jefferson Hospitals, Philadelphia, PA.
    Research Fellow. Young Investigator Award Recipient and Symposia
    Speaker, Oxygen Society meeting Young Oncologist Essay Award and
    Symposia Speaker, American Radium Society International. First
    Author, J. Biol. Chem. 274:23061-23067 2000.

-   Regina Clemens, M.D., Ph.D. (1997- 2001). Pediatric Resident UCSF.
    Undergraduate student. Graduated MSTP 2007, University of
    Pennsylvania, Philadelphia, PA. Co-first author, J. Biol. Chem.
    274:23061-23067 2000.

-   Ana Botero, M.D. (1997-1998). Resident, Radiation Oncology,
    Currently an Assistant Professor, Washington University School of
    Medicine, St. Louis, MO. North American Hyperthermia Society
    Research Travel Award and Symposia Speaker, International Meeting,
    04/99. American Society of Therapeutic Radiation Oncology symposia
    speaker, 10/99. Author, J. Biol. Chem. 274:23061-23067.

-   David Diamond, M.D. Chief Resident, Radiation Oncology Center, and
    Section of Cancer Biology, Mallinckrodt Institute of Radiology,
    Washington University School of Medicine, St. Louis, MO. Radiation
    Research Travel Award and Symposia Speaker at the Radiation Research
    Society meeting, 4/98. ASTRO Resident Basic Science Research Award,
    and ASTRO symposia speaker, 10/98. The National Institute of Health,
    Mentor Clinical Scientist Development Award (K08). 04/99 until
    04/05. RE: 1KO8 CH81033-01. (\$383,218 direct and \$413,876 total
    cost).

[Memberships:]{.underline}

-   American Society of Radiation Therapeutic Oncology

-   American Society of Cancer Research

-   Radiological Society of North American

-   International Society of Radiation Research

[Medical Licensure and Board Certification]{.underline}

Missouri Medical licensure, 1994.

Diplomat, American Board of Radiology, 1999.

Michigan Medical licensure, 1993.

Illinois Medical licensure, 1992.

**[Copyrights and Patents:]{.underline}**

1.  Wink, D.A., Miranda, K.M., Bradbury, C.M., Gius, D., Fukuto, J.M.,
    Feelisch, M. Cyclooxygenase Inhibition with Nitroxyl. New U.S.
    patent application filed (12 May 2004) #E-301-2002/0-US-01, United
    States Patent and Trademark Office.

**[Chapters:]{.underline}**

1\. Conley BA, Forastierre A, Gius D, and Van Waes C. Head and Neck
Cancer. In, Bethesda Handbook of Clinical Oncology, 2nd Ed., J Abraham
Ed., Lippincott Williams and Wilkins, Philadelphia, PA, 2005 pp3-31.

**[Publications:]{.underline}**

1\. Collins, M.A., Neafsey, E.J., Cheng, B.H., Hurley, K.M., Ung-Chun,
N.A., Pronger, K., Christensen, D.M., and [Gius D]{.underline}.
Endogenous analogs of N-methyl-4-,2,3,6-tetrahydro-pyridine: Indoleamine
derived tetra hydro-beta-carboline as causative factors in Parkinson's
disease. *Adv. Neurology* 45:179-182, 1985.

2\. [Gius, D]{.underline}., Grossman, S., Bedell, M.A., and Laimins,
L.A. Inducible and constitutive enhancer domains in the human
papillomavirus type-18 noncoding region. *J. Virol.* 62:665-672, 1988.

3\. [Gius, D]{.underline}., and Laimins, L.A. Activation of human
papillomavirus type-18 genes by herpes simplex virus type 1 viral
trans-activators and phorbol esters. *J. Virol.*63: 555-563, 1989.

4\. [Gius, D]{.underline}., Coa, X., Rauscher, III, F., Cohen, D.R.,
Curran, T., and Sukhatme V.P. Transcriptional activation and repression
by *Fos* are independent functions: the C-terminus represses immediate
early gene expression via CArG elements. *Mol. Cell. Biol.*
10:4243-4255, 1991.

5\. Rim, M., Qureshi, J., [Gius, D.]{.underline}, Nho, J., Sukhatme,
V.P., and Foster D.A. (1991) Differential activation of serum responsive
elements in the *Egr-1* promoter by *v-Src* and *v-myc*. *Oncogene*
7:2065-2080, 1992.

6\. [Gius, D]{.underline}., Hallahan, D., Kuchibhotla, H., Sukhatme,
V.P., Kufe, D., and Weichselbaum R.R. (1990) Radiation signaling
mediated by Jun activation following dissociation a cell type-specific
repressor. *J. Biol. Chem.* 268:4903-4907, 1993.

7\. Ezhevsky, S.A., Vocero-Akbani, A.M., Nagahara, H., [Gius,
D]{.underline}., Wei, M.C., and Dowdy S.F. Hypo-phosphorylation of the
retinoblastoma protein by cyclin D:cdk4/6 results in active *pRb*.
*Proc. Natl. Acad. Sci.* USA 94:10699-10704, 1997.

8.  [Gius, D]{.underline}. The *p53* gene and intrinsic cellular
    radiosensitivity in Tumor cells. *Breast Disease* 9:22-24, 1998.

9.  [Gius, D.]{.underline}, Ezhevsky, S.A., Becker-Hapak, M., Nagahara,
    H., Wei, M.C., and Dowdy, S.F. Transduced *p16INK4a* peptides
    inhibit hypo-phosphorylation of the retinoblastoma protein and cell
    cycle progression prior to activation of cdk2 complexes in late G1.
    *Cancer Research* 59:2577-80, 1999.

10. [Gius]{.underline}, D., Botero, A., Shah, S., and Curry, H.A.
    Intracellular oxidation/reduction status in the regulation of
    transcription factors AP-1 and NF-B. *Toxicology Letters*
    106:93-106, 1999.

```{=html}
<!-- -->
```
11. Diamond D.A., Parsian, A., Hunt, C.R., Lofgren, S., Spitz, D.R.,
    Goswami, P, and [Gius, D.]{.underline} Redox Factor-1 (*Ref-1*)
    mediates the activation of AP-1 in HeLa and NIH 3T3 cells in
    response to heat. *J. Biol. Chem.* 274:16959-16964, 1999.

12\. Curry, H.A., Clemens, R.A., Shah, S., Bradbury, C.M., Botero, A.,
Goswami, P, and [Gius, D]{.underline}. Heat Shock inhibits
radiation-induced nuclear localization and activation of NF-B
DNA-binding. Possible role in radiation sensitization of tumor cells.
*J. Biol. Chem.* 274:23061-23067, 1999.

13. Wei, J., Botero, A., Hirota, K.**,** Bradbury, C.M., Markovina,
    Bradbury, C.M., Laszlo, A., Spitz, D.R., Goswami, P.C., Yodoi, J.,
    and [Gius, D.]{.underline} Thioredoxin nuclear translocation and
    interaction with redox factor-1 activate the AP-1 transcription
    factor in response to ionizing radiation. *Cancer Research* 60,
    6688-6695, 2000.

14\. Goswami, P.C., Sheren, J., Albee, L.D., Parsian, A., Sim, J.E.,
Ridnour, L.A., Higashikubo, R., Hunt, C.R., [Gius, D.]{.underline}, and
Spitz, D.R. Cell Cycle Coupled Variation in Topoisomerase II mRNA is
regulated by the 3' Untranslated Region: Possible Role of Redox
Sensitive Protein Binding in mRNA levels. *J. Biol. Chem.* 275:
38384-38392, 2000.

15\. Vocero-Akbani, A., Lissy, N.A., Nagahara, H., Snyder, E.L., Ho, A.,
Latham, D.G., Becker-Hapak, M., [Gius, D.]{.underline}, Ezhevsky, S.A.
and Dowdy, S.F. HIV TAT protein as a protein transduction system to
introduce proteins in cells. *Methods in Enzymology,* Reed, J.C., (ed).
Vol. 311, pp 508-50-21, 2000.

16\. Roti Roti, J.L., [Gius, D.]{.underline}, VanderWall, R.P., and Xu,
M. Changes in sub-nuclear structures and functional perturbations:
Implications for radiotherapy. *J. Cell. Biochem.* 35:142-150, 2000.

17\. Bradbury, C.M., Locke, J.E., Wei, J., Rene, L., Karimpour, S.,
Hunt, C. R., Spitz, D.R., and [Gius, D.]{.underline} Increased AP-1
Activity As Well As Resistance to Heat-Induced Radiosensitization,
H~2~O~2~, and Cisplatin are Inhibited by Indomethacin in Oxidative
Stress Resistant Cells. *Cancer Research* 61: 3486-3492, 2001.

18. Bradbury, C.M., Markovina, S., Wei, J., Renee, L.M., Zoberi, I.,
    Horikoshi N, and [Gius, D]{.underline}. The Role of NF-B as One
    Downstream Target of *p38^MAPK^* in the Process of
    Indomethacin-induced Radiosensitization. *Cancer Research* 61:
    7689-7696, 2001.

19. Zoberi, I., Bradbury, C, M., Curry, H.C., Bisht, K.S., Goswami,
    P.C., Roti Roti, J.L., and [Gius, D.]{.underline} The Roles of
    Radiosensitizing as Well as Anti-Proliferative Effects of
    Resveratrol in Two Human Cervical Tumor Cell lines. *Cancer Letters*
    175: 165-173, 2001.

20. Locke, J.E., Bradbury, C.M., Wei, J., Shah, S., Renee, L.M.,
    Clemens, R.A., Roti Roti, J.L., Horikoshi N, and [Gius,
    D]{.underline}. Indomethacin Lowers the Threshold Thermal Exposure
    for Hyperthermic Radiosensitization and Heat Shock Inhibition of
    Ionizing Radiation-Induced NF-B. *Int. J. Radiat. Biol.* 78:493-502,
    2002.

21. Sekhar, K., Spitz, D., Harris, S., Nguyen, T., Meridith, M., Holt,
    J., and [Gius, D.]{.underline}, Marnett, L., Summar, M., and
    Freeman, M. Redox-sensitive interaction between *KIAA0132* and
    *Nrf2* mediates indomethacin-induced expression of -glutamylcysteine
    synthetase. *Free Radic. Biol. Med.* 32:650-662, 2002.

22. Aft, R., Zhang, F., and [Gius, D.]{.underline} Evaluation of
    2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell
    death. *British Journal of Cancer* 87:805-812, 2002.

23. Karimpour, S., Lou, J., Lin, L.L., Rene, L.M., Lagunas, L., Ma, X.,
    Karra, S., Bradbury, C.M., Markovina, S., Goswami, P.C., Spitz,
    D.R., Hirota, K., Kalvakolanu, D.V., Yodoi, J., and [Gius,
    D.]{.underline} Thioredoxin Reductase Regulates AP-1 Activity as
    well as Thioredoxin Nuclear Localization via Active Cysteines in
    Response to Ionizing Radiation. *Oncogene* 12:6317-6327, 2002.

24. Ohiro, Y., Garkavtsev, I., Duffy, S.L., Kobayashi, S., Sreekumar,
    K.R., Nantz, R., Higashikubo, B.T., Duffy, S.L., Higashikubo, R.,
    Usheva, A., [Gius, D.]{.underline}, Kley, N., and Nobuo
    Horikoshi, N. A novel *p53*-inducible apoptogenic gene *PRG3*,
    encodes for a homologue of the apoptosis-inducing factor (AIF).
    *FEBS Letters* 524:163-171, 2002.

25. [Gius, D.]{.underline}, and Coleman, C.N. Treatment of
    Nasopharyngeal Cancer: Raising the"Barr". *J. Natl. Can. Inst.*
    94:1594-1595, 2002.

26. Ohiro, Y., Usheva, A., Duffy, S.L., [Gius, D,]{.underline} and
    Horikoshi, N. Tumorigenic mutant p53 inhibits stress-inducible
    kinase pathway and restores growth suppression. *Mol. Cell. Biol.*
    23:322-334, 2003.

27. Karimpour, S., and [Gius, D.]{.underline} The Holy Grail of
    Radiation Oncology: Lessons learned from Hyperthermia. *Int. J.
    Radiation Oncology Biol. Phys.* 55:3-4, 2003.

28. Lin, X., Aft, R., Spitz, D.R., and [Gius, D.]{.underline} Cytotoxic
    and Radiosensitizing Effects of 2-Deoxy-d-Glucose on HeLa Cells.
    *Cancer Research* 63:3413-3417, 2003.

29. Bisht, K., Bradbury, C.M., Zoberi, I., Curry, H.A., Rader, J.S., and
    [Gius, D.]{.underline} Inhibition of *Cyclooxygenase-2* With NS398
    Inhibits Radiation-induced Transformation, Micronuclei Formation,
    and Clonogenic Cell Death. *Int. J. Rad. Biol.* 79:879-888, 2003.

30. Bisht, K., Bradbury, C.M., Mattson, D., Kaushal, A., Sowers, A.,
    Markovina, S., Ortiz, K., Sieck, L.K., Isaacs, J.S., Brechbiel,
    M.W., Mitchell, J.B., Neckers, L.M., and [Gius, D.]{.underline}
    Increased Radiosensitization in Cervical Tumor Cells Geldanamycin
    and 17-Allylamino-17-Demethoxygeldanamycin Potentiates the Radiation
    Response of Cervical Tumor Cells In Vitro and In Vivo. *Cancer
    Research* 63:8984-8995, 2003.

31. Lagunas, L., Bradbury, C.M., Hunt, C.R., and [Gius, D.]{.underline}
    Indomethacin and Ibuprofen Induce HSC-70 Nuclear Localization and
    Activation of the Heat Shock Response in HeLa Cells. *Biochem
    Biophys Res Commun*. 313:863-870, 2004.

32. [Gius, D.]{.underline}, Mattson, D., Bisht, K., Bradbury, C.M., and
    Spitz, D.R. Thermal Stress both Activates and Inhibits Redox
    Sensitive Signaling and Transcription Factors: Possible role in
    radiosensitization. *Int. J. Hyperthermia* 20:213-223, 2004.

33. Cook, J.A., [Gius, D.]{.underline}, Wink, D.A., Krishna, M.C.,
    Russo, A., and Mitchell, J.B. Oxidative Stress, Redox, and the Tumor
    Microenvironment. *Semin. Radiat. Oncol*. 23:311-322, 2004.

34. Mimnaugh, E.G., Wanping, X., Vos, M., Yuan, X., Isaacs, J.S., Bisht,
    K.S., [Gius, D.]{.underline}, and Neckers, L. Target the HSP90
    Molecular Chaperone with Geldanamycin, While Inhibiting Proteasomal
    Proteolysis with Bortezomib, Promotes Protein Ubiquitination, Causes
    ER-Derived Cytosolic Vacuolization and Enhances Antitumor Activity.
    *Mol. Cancer Ther.* 3:551-566, 2004.

35. Mattson, D., Bradbury, C.M., Bisht, K., Spitz, D.R., and [Gius,
    D.]{.underline} Heat Shock Upregulates AP-1 and Inhibits NF-B
    Activity: Possible role in radiosensitization of tumor cells.
    *Int. J. Hyperthermia* 20:224-233, 2004.

36. Spitz, D.R., Azzam, E.I., Li, J.J., and [Gius, D.]{.underline}
    Metabolic Oxidation/Reduction Reactions and Cellular Reponses to
    Ionizing Radiation: A Unifying Concept in Stress Response Biology.
    *Cancer Metastasis Rev.* 23:311-322, 2004.

37. Smart, D., Ortiz, K., Mattson, D., Bradbury, C.M., Bisht, K., Sieck,
    L.K., Brechbiel, M.W., and [Gius, D.]{.underline} Thioredoxin
    Reductase as a Molecular Target for Anti-Cancer Agents that induce
    Oxidative Stress. *Cancer Research* 64:6716-6724, 2004.

38. [Gius, D.]{.underline}, Cui, H., C., Bradbury, M.C., Cook, J.,
    Smart, D., Zhao, S., Young, L., Brandenburg, Bisht, K., Ho, A.S.,
    Mattson, D., Sun, L., Munson, P.J., Chuang ,E.Y., Mitchell, J.B.,
    and Feinberg, A. Distinct Effects on Gene Expression of Chemical and
    Genetic Manipulation of the Cancer Epigenome Revealed by a
    Multimodality Approach. *Cancer Cell* 6:361-371, 2004.

39. [Gius, D.]{.underline} Redox-sensitive signaling factors and
    antioxidants: how tumor cells respond to ionizing radiation. *J.
    Nutr*. 134:3213-3214, 2004.

40. Wang, T., Hu, Y.C., Dong, S., Fan, M., Tamae, D., Ozeki, M., Gao,
    Q., [Gius, D.]{.underline}, and Li, J.J. Co-activation of *ERK*,
    *NF-B* and *GADD45* in response to ionizing radiation. *J. Biol.
    Chem.* 280:12593-126012, 2005.

41. Bjornsson, H.T., [Gius, D.]{.underline}, and Feinberg, A.P The new
    field of epigenomics: implications for cancer and other common
    disease research. *Epigenetics and Cancer,* Cold Spring Harb. Symp.
    Quant Biol. 69:447-456, 2005.

42. Nguyen, P., Awwad, R.T., Smart, D.D.K., Spitz, D.R., and [Gius,
    D.]{.underline} Thioredoxin reductase as a novel molecular target
    for cancer therapy. *Cancer Letters*, 236:164-174, 2005.

43. Van Waes, C., Chang, A., Lebowitz, P.F., Harkins, C., Chen, Z.,
    Elsayed, Y., Sunwoo, J.B., Headlee, D., Rudy, S.F., Adams, J.,
    Morris, J., Mitchell, J.B., Camphausen, K., [Gius, D.]{.underline},
    Sausville, E.A., Conley, B. Clinical and Biologic Effects of
    Concomitant Therapy With Proteasome Inhibitor Bortezomib and
    Re-irradiation in Patients with Recurrent Head and Neck Squamous
    Cell Carcinoma. *Int. J. Rad. Oncol. Biol. Phys*. 63:1400-1412,
    2005.

44. Pennington, J.D., Wang, T.J.C., Phuongmai Nguyen, Sun, L., Bisht,
    K., Smart, D., and [Gius, D.]{.underline} Redox-Sensitive Signaling
    Factors as a Novel Molecular Targets for Cancer Therapy. Resistance
    to epidermal growth factor receptor-targeted therapy. *Drug Resist
    Updat* 8:322-30, 2005.

45. [Gius, D.]{.underline}, Bradbury, C.M., Su, L., Awwad, R.T., Huang,
    L., Smart, D.D.K., Bisht, K.S., Ho, A.S., and Nguyen, P. The
    Epigenome as a Molecular Marker and Target: Implications for Cancer.
    *Cancer* 9:1789-1793 2005.

46. Stoyanovsky, D.A., Tyurina, Y.Y., Tyurin, V.A., Anand, D.,
    Mandavia, D.N., [Gius, D.]{.underline}, Ivanova, J., Pitt, B.,
    Billiar, T.R., and Kagan, V.E. A new regulatory role of thioredoxin:
    S-denitrosation of proteins and low molecular weight
    S-nitrosothiols. *J. Am. Chem. Soc*. 16:127:15815-23, 2005.

47. Fitzpatrick, M., Funk, M., [Gius, D.]{.underline}, Huettner, P.,
    Zhang, Z., Bidder, M., Ma, D., Powell, M., Rader, J. Identification
    of chromosomal alterations important in the development of cervical
    intraepithelial neoplasia and invasive carcinoma using alignment of
    DNA microarray data. *Gynecologic Oncology*, (Apr 26), 2006.

48. Barker, C.A., Burgan, W.E., Carter, D.J., Cerna, D., [Gius,
    D.]{.underline}, Hollingshead, M.G., Camphausen, K., Tofilon, P.J.
    *In vitro* and *in vivo* radiosensitization induced by the
    ribonucleotide reductase inhibitor triapine
    (3-aminopyridine-2carboxaldehyde-thiosemicarbazone). *Clin. Can.
    Res.* 12: 2912-2918, 2006.

49. Zhao, W., Chuang, E.Y., Mishra, M., Awwad, R., Bisht, K., Sun, L.,
    Nguyen, P., Pennington, J.D., Wang, T.J., Bradbury, C.M., Huang, L.,
    Chen, Z., Bar-Sela, G., Robbins, M.E., and [Gius, D.]{.underline}
    Distinct Effects of Ionizing Radiation on *In Vivo* Murine Kidney
    and Brain Normal Tissue Gene Expression. *Clin. Can. Res.*
    12:3823-3830, 2006.

50. [Gius, D.]{.underline}, and Spitz, D. R. Redox Signaling in Cancer
    Biology. *Antioxidants and Redox Signaling* 8:1249-1252, 2006.

51. Bar-Sela, G, Muldoon Jacobs, K., and [Gius, D.]{.underline}
    Chromatin Compaction and the Radiation Response by Cancer Cells.
    *The Cancer Journal* 65-69, 2007

52. [Gius, D.,]{.underline} Funk, M., Chuang, E.Y., Feng, S., Huettner,
    P.C., Nguyen, L., Mishra, M., Gao, S., Barbara M. B., Cohn, D.E.,
    Powell, M.A., Horowitz, N.S., Whitcomb, B.P., and Rader, J.S.
    Distinct Gene Expression Signatures of CIN HPV Infected Cervical
    Epithelial and Stoma tissue revealed by laser-dissection
    microscopy-assisted Microarray Profiling. *Cancer Research*
    67:7113-7123, 2007. (Featured on the Journal Cover)

53. Annunziata, C.M., Kleinberg, L., Davidson, C., Berner, A., [Gius,
    D.]{.underline}, Tchabo, N., Steinberg, S.M. and Kohn, E.C.
    *BAG-4*/*SODD* and Associated Anti-Apoptotic Proteins are Associated
    with Aggressiveness of Epithelial Ovarian Cancer. *Clin. Can. Res.*
    13:6585-6592, 2007.

54. Pennington, J.D., Muldoon Jacobs, K. Sun, L., Bar-Sela, g., Mishra,
    M., and [Gius, D.]{.underline} Thioredoxin and Thioredoxin Reductase
    as Redox-Sensitive Signaling Factors as Potential Molecular Targets
    for Cancer Therapy. *Curr. Pham. Design*. 33:3368-3377, 2007.

55. Guo, Z., Tsai, M, H., Shiao, Y.H., Chen, L.H., Wei, M.L., Lv, X.,
    [Gius, D.]{.underline}, Little, J.B., Mitchell, J.B., and Chuang,
    E.Y. DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant
    *p53*-determined *p16^(ink4A)^* down-regulation. *J. Biomed. Sci.*
    2007.

56. Yu, W., [Gius, D.]{.underline}, Karp, J., Sun, L., Feinberg, A.P.,
    and Cui, H. Epigenetic silencing of tumour suppressor gene *p15* by
    its antisense RNA. *Nature* 451:202-206, 2008.

57. Mishra, M.V., Bisht, K.S., Muldoon Jacobs, K., Awwad, R., Kaushal,
    A., Nguyen, P., Sun, L., Huang, L., Pennington, J.D., Markovina, S.,
    Bradbury, C.M., and [Gius, D.]{.underline} *DNMT1* as a Molecular
    Target in a Multi-Modality Resistant Phenotype in Tumor Cells.
    *Mol.* *Can. Res.* 6:243-249, 2008.

58. Sun, L., Huang, L., Nguyen, P., Bisht, K.S., Bar-Sela, G., Ho, A.,
    Ho, A., Bradbury, C.M., Yu, W., Cui, H., Lee, S., Trepel, J.B.,
    Feinberg, A.P., and [Gius, D.]{.underline} DNA methyltransferase 1
    and 3B activate *BAG-1* expression via recruitment of CTCFL/BORIS
    and modulation of promoter histone methylation. *Cancer Research*
    68:2726-2735, 2008.

59. Nguyen, P., Sun, L., Cui, H., Bisht, K.S., Lee, R.S., Kogoh, H.,
    Oshimura, M., Patel, K., Feinberg, A.P., [Gius, D.]{.underline}
    *CTCFL*/*BORIS* is a methylation-independent DNA-binding protein
    that preferentially binds to the paternal H19 DMR *Cancer Research*
    68: 5546-5551, 2008.

60. Trimble, E.L., Harlan, L.C., [Gius, D.]{.underline}, Stevens, J.,
    Schwartz, S.M. Patterns of Care for Women with Cervical Cancer in
    the US. *Cancer* 113:743-749., 2008.

61. Jacobs, K.M Pennington, D., Bisht, K.S., Aykin-Burns, N., Kim, H-S.,
    Mishra, M., Sun, L Nguyen, P., Ahn, B-H., Deng, C-X., Spitz, D.R.,
    and [Gius, D.]{.underline} SIRT3 interacts with the daf-16 homolog
    FOXO3a in the Mitochondria, as well as increases FOXO3a Dependent
    Gene expression. *Int. J. Biol. Sci.* *Int J Biol Sci.* 4:291-299,
    2008.

62. Nguyen, P., Bar-Sela, G., Sun, L., Cui, H., Bisht, K.S., Kohn, E.,
    Feinberg, A.P., and [Gius, D.]{.underline} *SET1*/*MLL* forms a
    complex with BAT3 and *CTCFL*/*BORIS* modulate H3K4 histone
    dimethylation and gene expression. *Mol. Cell. Biol*. 28:6720-6729,
    2008.

63. Hadley Sharp, H., Morris, J.C., VanWaes, C., [Gius, D.]{.underline},
    Cooley-Zgela, T., Singh, A.K. High Incidence of Oral Dysesthesias on
    a Trial of Gefitinib, Paclitaxel, and Concurrent External Beam
    Radiation for Locally Advanced Head and Neck Cancers. *Amer. J.
    Clin. Oncol.* 31:557-560, 2008.

64. Rader, J.S., Malone, J.P., Gilmore, P., Brooks, R.A., Nguyen, L.,
    Crimmins, D.A., Feng, S., Wrigh, J.D Taylor, N., Zighelboim, I.,
    Funk, M.C., Huettner, P.C., Ladenson, J.H., [Gius, D.]{.underline},
    Townsend, R.R. Sample Preparation and Proteomic Profiling of
    Cervical Swabs to Identify Biomarkers for Cervical Cancer Screening.
    *Proteomics* (In press), 2008.

65. Jareer N. Kassis, J.N., Virador, V.M., Guancial, A.G., Kimm, D., Ho,
    A.H., Mishra, M., Chuang, E.Y., Cook, J., [Gius, D.]{.underline} and
    Kohn, E.C. Genomic and Phenotypic analysis reveals a key role for
    CCN1 (CYR61) in BAG3 -- modulated adhesion and invasion.
    (Submitted), 2008.

66. Patel, K., Muldoon-Jacobs, K., Aykin-Burns, N., Hyun-Seok Kim, H-S.,
    Pennington, J.D., van der Meer, R., Bisht, K.S., Nguyen, P., Savage,
    J., Owens, K., Singh, K.K., Abdulkadir, S.A., Deng, C-X.., Spitz,
    D.R., and [Gius, D.]{.underline} Loss of Mitochondrial integrity in
    Knockout SIRT3 Primary Cells Results in a Tumor Permissive
    phenotype. (Submitted), 2008.

67. Van Waes, C., Allen, C., Citrin, D., David [Gius, D.]{.underline},
    Colevas, A.D., Harold, N., Rudy, S., Nottingham1, L., Muir, C.,
    Chen, Z., Singh, A.K., Dancey, J., Morris, J.C.. Molecular and
    Clinical Responses to Gefitinib Combined with Paclitaxel and
    Radiation in Patients with Locally Advanced Head and Neck Cancers
    from a Pilot Phase I Clinical Study. (Submitted), 2008.

> C. Norman Coleman, M.D.
>
> Center of Cancer Research,
>
> National Cancer Institute
>
> National Institutes of Health,
>
> Bethesda, MD.
>
> \(301\) 496-5457
>
> Email: ccoleman@mail.nih.gov

Ted Lawrence, M.D., Ph.D.

Professor and Chairman

Department of Radiation Oncology

University of Michigan Medical Center

Ann Arbor, MI.

(734)647-9955

> Email: <tsl@med.umich.edu>
>
> Vikas Sukhatme, M.D., Ph.D.
>
> Director and Division Head
>
> Department of Nephrology
>
> Beth Israel Hospital
>
> 330 Brookline Avenue
>
> Harvard Medical School
>
> Boston, MA.
>
> \(617\) 667-2105
>
> Email: <vsukhatm@caregroup.harvard.edu>